The Effects of Steroids on Survival of Mouse and Human Tympanic Membrane Fibroblasts

• Published in: Otolaryngology-head and neck surgery p. 194599820912739
• Main Authors: Karnani, David N, Dirain, Carolyn O, Antonelli, Patrick J
• Format: Journal Article
• Language: English
• Published: England 01.08.2020
• Subjects: fibroblasts; steroids; ear drops; cytotoxicity; tympanic membrane
• ISSN: 1097-6817
• DOI: 10.1177/0194599820912739

Tympanic membrane (TM) fibroblast cytotoxicity of quinolone ear drops is enhanced by dexamethasone and fluocinolone. Hydrocortisone has not been evaluated. We aimed to assess the effects of these 3 steroids on mouse and human TM fibroblast survival. In vitro. Academic laboratory. Mouse and human TM fibroblasts were exposed to hydrocortisone, dexamethasone, or fluocinolone at concentrations in commercial ear drops (1%, 0.1%, or 0.025%, respectively) and at steroid potency equivalents (1%, 0.033%, or 0.0033%, respectively), or dilute ethanol (control), twice within 24 hours or 4 times within 48 hours for 2 hours each time. Cells were observed with phase-contrast microscopy until the cytotoxicity assay was performed. Mouse and human TM fibroblasts treated with any of the steroids had lower survival after 24 and 48 hours compared to control (all < .0001). After 24 hours, viability of mouse fibroblasts treated with the steroids was not different ( > .05), while treatment with hydrocortisone decreased human TM fibroblast viability ( < .0001). After 48 hours, at concentrations found in ear drops and at equivalent steroid potency, dexamethasone and fluocinolone had similar survival in mouse and human fibroblasts (all > .05), but hydrocortisone had lower survival in both mouse ( = .02 and < .0001) and human ( < .0001) fibroblasts. Phase-contrast images mirrored the cytotoxicity findings. Steroids found in commercial ear drops reduce survival of mouse and human TM fibroblasts. Hydrocortisone appears to be more cytotoxic than the more potent steroids, dexamethasone and fluocinolone. These findings should be considered when assessing clinical outcomes of ototopical preparations.